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Background: Patient encounters for medically unexplained physical symptoms are common in primary health
care. Somatization (‘experiencing and reporting unexplained somatic symptoms’)may indicate concurrent or fu-
ture disability but this may also partly be caused by psychiatric disorders. The aim of this study was to examine
the cross-sectional and longitudinal association between somatization and disability in primary care patients
with and without anxiety or depressive disorder.
Methods: Data were obtained from 1545 primary care patients, participating in the longitudinal Netherlands
Study of Depression and Anxiety (NESDA). Somatization was assessed using the somatization scale of the
Four-Dimensional Symptom Questionnaire (4DSQ). Disability was determined by the WHO Disability Assess-
ment Schedule 2.0 (WHO-DAS II). The relationships between somatization and both the total and subdomain
scores of the WHO-DAS II were measured cross-sectionally and longitudinally after one year of follow-up
using linear regression analysis.We examinedwhether anxiety or depressive disorder exerted amodifying effect
on the somatization-disability association.
Results: Cross-sectionally and longitudinally, somatization was signiﬁcantly associated with disability. Somatiza-
tion accounted cross-sectionally for 41.8% of the variance inWHO-DAS disability and, longitudinally, for 31.7% of
the variance in disability after one year of follow-up. The unique contribution of somatization to disability de-
creased to 16.7% cross-sectionally and 15.7% longitudinally, when anxiety and/or depressive disorder was
added to the model.
Conclusion: Somatization contributes to the presence of disability in primary care patients, evenwhen the effects
of baseline demographic and health characteristics and anxiety or depressive disorder are taken into account.© 2015 Elsevier Inc. All rights reserved.Introduction
In primary care patients, somatization is a common problem. A sub-
stantial amount of patient encounters in primary care concern medical-
ly unexplained physical symptoms, leading to frequent consultations
and high overall health care costs [1]. Part of the patients with MUScine of theUniversity of Utrecht,
for Primary Care, Institute of
mson Building, Oxford Road,
Leeuw),
).fulﬁll the criteria for somatization, or a somatoform disorder. Several
deﬁnitions and operationalizations of somatization have been pro-
posed, frequently including ‘the expression of psychological illness
through physical symptoms’ [2] as well as ‘repeated medical help-
seeking for multiple medical symptoms without organic disease’ [3].
The presence of medically unexplained physical symptoms is a key fea-
ture of somatoform disorders [4]. In a systematic review about the prev-
alence and disability burden of mental and neurological disorders in the
European Union, a 12-month prevalence of somatoform disorders of
6.3% was found [5]. Other studies reported a prevalence of undifferenti-
ated somatoform disorders varying from 8.6% up to 25.6% in primary
care patients [6–9]. Somatoform disorders include somatization disor-
der and undifferentiated somatoform disorders [4].
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cross-sectional studies [10–12]. The World Health Organization de-
scribes disability as ‘any restriction or lack of capacity to perform
an activity in a manner or within a range considered normal for a
human being’ [13]. The presence of ﬁve or more medically unex-
plained symptoms is associated with greater social disability com-
pared to ﬁve symptoms with a medical explanation [14]. Patients
with long-lasting somatization have more disability and higher sick
leave than non-somatizers [12]. Up to 30% do not recover or even
get worse, indicating a poor prognosis for a substantial group [15].
High levels of somatic symptom severity contribute to reduced
health-related functioning [16,17], even after adjustment for psychi-
atric and medical co-morbidity [1,18].
The linkwith anxiety and depression has beenmentioned often and
the term cosyndromality has been suggested for the concurrent occur-
rence of somatic, anxiety and depressive symptoms [19]. In primary
care, somatizing patients often have comorbid anxiety or depressive
disorders [20]. Three quarters of somatizing patients for whom psychi-
atric consultationwas requested by a general practitioner (GP) in a con-
sultation trial, turned out to have undetected depression or anxiety
disorder [21]. De Waal and colleagues found that 50% of the primary
care patients with an anxiety and/or depressive disorder also had a co-
morbid somatoform disorder [22]. This suggests that this combination
of symptoms and syndromes poses a clinical challenge for the GP.
However, most of this research was cross-sectional and it has rarely
been explored if somatization in itself leads to long-term disability, or
whether concurrent ill mental health, especially anxiety and depressive
disorder, is responsible for the somatization–disability connection. Pre-
vious studies that investigated the association between somatization
and disability in primary care patients identiﬁed psychiatric morbidity
as a potential confounder of this relationship [18], but no studies were
performed with a longitudinal design. However, if such an association
would exist, this could have far-reaching clinical consequences. Perhaps
patients who are somatizing with comorbid psychiatric disorders show
more disability compared to people with only somatization or psychiat-
ric disorder. That would indicate that they should at least receive treat-
ment both for the psychiatric problems and for the somatic symptoms.
The aimof our studywas, therefore, to investigate the effect of soma-
tization on disability in primary care patients, both cross-sectionally,
and during longer follow-up. We addressed the following research
questions: 1) Is somatization cross-sectionally and/or longitudinally
associated with disability over the course of a year in primary care
patients?; and 2) if that is the case, is this association the same in pa-
tients with and without depressive or anxiety disorder (i.e., is the asso-
ciation modiﬁed by depressive or anxiety disorder)?
Methods
Design
We carried out an observational study with both cross-sectional
and longitudinal analyses after one year of follow-up in primary care
patients.
Participants and procedure
Data were obtained from the Netherlands Study of Depression and
Anxiety (NESDA), a multicenter cohort study including a representative
sample of participants aged 18 through 65 years old. Participants were
recruited from the general population, primary care and secondary
mental health care. Multidimensional information was collected
through interviews, self-report questionnaires and various tests. A de-
tailed description of the objectives and methods of the NESDA study
has been published elsewhere [23].
For the current study, we selected the subsample of primary care
patients being a stratiﬁed sample of consecutive primary careattendees. Participants who did not complete the questionnaires
used in this study or who had too many missing values (see below)
were excluded.
For the longitudinal analyses, the same sample was used as for the
cross-sectional analyses with the exclusion of the participants who
had too many missing values, and therefore could not be imputed, on
the WHODAS at one year of follow-up.
Measures
Somatization
Somatization was measured with the 16-item Somatization scale of
the Four-Dimensional Symptom Questionnaire (4DSQ), as it is a valid
questionnaire to measure somatization in the primary care setting
[24]. The questionnaire is designed to assess common psychological
symptoms in primary care. It contains a continuous scale with a range
from 0 to 32. Experiencing many symptoms from different organ sys-
tems (e.g. dizziness and upset stomach and palpitations and muscular
aches) implies somatization [25]. In patients presentingwith (medically
unexplained) physical symptoms, scores on the 4DSQ-somatization
scale are signiﬁcantly associated with general practitioners' suspicions
of psychosocial factors playing a role in the presentation of these symp-
toms. [24] The 4DSQ-somatization questionnaire was used as a contin-
uous scale (range 0–32).
Disability
Disability wasmeasured using the self-reportWorld Health Orga-
nization Disability Assessment Schedule 2.0 (WHO-DAS II) [26]. This
instrument was created in 1998 and can be used as a common, inter-
national, and interdisciplinary instrument to measure disability. The
scale contains 36 items on functioning and disability, covering six
domains of functioning during the last 30 days: 1. Understanding
and communicating with the world (cognition); 2. Moving and get-
ting around (mobility); 3. Hygiene, dressing, eating, and staying
alone (self-care); 4. Getting along with people (interpersonal inter-
actions); 5. Work, leisure, domestic responsibilities (life activities);
6. Joining in community activities (participation in society) [26].
There is a fair correlation between the domains of the WHO-DAS
scales and similar domains in other equivalent instruments, such as
the SF-12, SF-36, theWHO Quality of life scale and the London Hand-
icap Scale [27].
Scores were calculated for the separate domains and all domains
combined. Subsequently, the scores were transformed into scores on a
scale from 0 to 100, where higher scores reﬂect greater disability.
Depressive and anxiety disorder
Baseline diagnoses of anxiety and depressive disorderwere based on
the Composite International Diagnostic Interview (CIDI, version 2.1),
according to the DSM-IV criteria. The CIDI is a robust diagnostic tool
with good reliability and validity [28]. We used current disorders
(i.e., occurring within the past month). Depressive disorders included
Major Depressive Disorder and Dysthymia, and anxiety disorders in-
cluded Generalized Anxiety Disorder, Panic Disorder with Agoraphobia,
Panic Disorderwithout Agoraphobia, Social Phobia and/or Agoraphobia.
For the analyses we deﬁned depression–anxiety status as a nominal
variable with 4 categories: no anxiety or depressive disorder, anxiety
disorder only, depressive disorder only, and comorbid anxiety with de-
pressive disorder.
Background variables
Basedon the literature, the following independent variableswere con-
sidered as potential confounders of the relationship between somatiza-
tion and disability: gender, age, marital status, education level, the
number of chronic somatic diseases anddepressive and anxiety disorders.
Table 1
Characteristics of the study population (weighted, N= 1545)
Characteristics
Mean (SD)
WHO-DAS 32 items (0–100) 13.30 (14.26)
4DSQ (0–32) 7.16 (6.29)
Percentage %
Personal characteristics
Age (in years)
b47 48.6
≥47 51.4
Gender (female) 67.2
Nationality (Dutch) 98.1
Married/partner 76.2
# Chronic diseases (0–8)
0 56.7
1 29.7
≥2 13.6
Education level
Basic 4.8
Intermediate 47.6
High 47.6
Illness characteristics
Anxiety disorder (past month)
Social phobia 8.1
Panic with agoraphobia 4.6
Panic without agoraphobia 2.3
Agoraphobia 3.1
GAD 5.8
Depressive disorder (past month)
Dysthymia 3.6
MDD 11.1
No anxiety/depressive disorder 77.1
Anxiety disorder only 11.0
Depressive disorder only 5.2
Comorbid anxiety-depressive disorder 6.7
119G. van der Leeuw et al. / Journal of Psychosomatic Research 79 (2015) 117–122These variables have all been linked to both somatization and disability to
some extent.
Gender, marital status, education level and number of chronic dis-
ease were obtained from the baseline interview. Marital status divided
the participants into two groups: thosewhoweremarried or had a part-
ner and those without a partner. Level of education was represented by
three categories (basic, intermediate and high) derived from the
SOI (standard classiﬁcation of education) of the CBS (Statistics
Netherlands). Chronic somatic diseases were measured by counting
the number of diseases (for instance heart diseases, asthma, diabetes
or arthritis) that participants reported forwhich theywere gettingmed-
ical treatment.
Continuous variables were split into categories (displayed in the
baseline table) to avoid problems with non-linear relationships and to
make results easier to interpret.
Statistical analysis
The analyses were conducted using data from primary care patients
with or without anxiety and depressive disorder. Because of the strati-
ﬁed sampling, we weighted back the study sample to the composition
of the source population using appropriate weights (see Donker et al.
[29]).
Respondents with two or more missing item scores on each of the
subscales of the WHO-DAS (three or more on subscale 6: participation
in society) or with 7 or more missing item scores on the somatization
scale were excluded. In the remaining respondents, missing item scores
were replaced with the participant's mean item score of the corre-
sponding scale.
As we focussed on the association between somatization and dis-
ability, we followed an explanationmodel approach [30]. We created
two linear regression models for both the cross-sectional and the
longitudinal analysis. The ﬁrst model explored the relationship be-
tween somatization as the independent variable and the WHO-DAS
II (total score and separate domain scores) as the dependent vari-
ables. The second model examined how much of this association
remained, after the addition of depression–anxiety status to the
ﬁrst model. To study the effect modiﬁcation, we added an interaction
term between somatization and depression–anxiety status. If the
‘causal’ effect of somatization on disability differs within strata of an-
other exposure, it is known as effect modiﬁcation [31]. A signiﬁcant
interaction term (p ≤ 0.01) was taken as a sign of effect modiﬁcation.
The p-value was based on Bonferroni correction for testing sixWHO-
DAS domains.
In both models, we tested background variables for being con-
founders in the relationship between somatization and disability by
including them as covariates in the regression models. Signiﬁcant con-
foundingwas deﬁned by a change of 10% or more in the beta coefﬁcient
of the somatization score. Signiﬁcant confounders were included in the
models to obtain unbiased estimates of the contribution of somatization
to disability [32]. Non-signiﬁcant confounders were not included in the
regression models.
We used the R-square statistic as a measure of effect size. In the ﬁrst
models without confounders, the model R-square represented the
amount of variance in the dependent variable (disability) explained by
the independent variable (somatization). In the secondmodels (with de-
pression–anxiety status), and also in theﬁrstmodels that included one or
more confounders, the model R-square represented the amount of vari-
ance in disability jointly explained by somatization and all covariates.
However, sincewewere only interested in the speciﬁc contribution of so-
matization to disability, we calculated R-square differences (delta R-
square) between the R-square of the full model and the R-square of the
covariate-only model (i.e., after removing somatization). Delta R-square
thus represented the amount of variance in disability explained by soma-
tization after adjusting for signiﬁcant confounders. The delta R square is
linked to the regression coefﬁcient. Those two measures are statisticallyequivalent. The association between somatization and disability is signif-
icant, when the regression coefﬁcient is signiﬁcant. Delta R square was
used as a measure of effect size.
All analyses were performed with SPSS 21.0.
Results
Characteristics of the study sample
Primary care patients were included (N=1610). Participants with toomanymissing
values on the WHO-DAS questionnaire or the 4DSQ somatization scale were excluded
(N = 32). This resulted in a total sample size of 1578 for the present analyses. After
weighting back to the composition of the source population, 1545 participants remained.
This overall sample had a mean age of 46.39 years old (SD = 11.94) with 67.2% women
and 32.8% men. The baseline characteristics of the participants are presented in Table 1.
Depressive and anxiety disorders were established in 22.9% of the weighted sample.
Cross-sectional association between somatization and disability
Table 2 summarizes the associations between somatization and disability in the vari-
ous domains. The relationship between somatization and disability was linear, and thus
we chose to analyze somatization as a continuous variable. The size of the effect of soma-
tization on disability is expressed in unstandardized regression coefﬁcients (B). For every
unit increase in the predictor, the somatization score, themeanWHO-DAS score increased
by the amount of the regression coefﬁcient B. For instance, one point increase in the soma-
tization scorewas associatedwith amean increase of 1.47 (95%CI 1.38; 1.55) in theWHO-
DAS total score (Table 2, ﬁrst line). The amount of variance in total WHO-DAS II score ex-
plained by somatizationwas 41.8%. Background variables turned out to be no confounders
of the relationship between somatization and disability, except for chronic diseases in the
relationship between somatization andmobility. Depression–anxiety status was no effect
modiﬁer of the relationship between somatization and disability total score. However,
after adjusting for anxiety and depressive disorder, the amount of WHO-DAS II total
score variance explained by somatization decreased from 41.8% to 16.7%. Thus, depression
and anxiety disorder accounted for 60% of the association between somatization and the
total disability score.
For the speciﬁc domains, the contribution of somatization to disability had a maxi-
mum explained variance of 37.5% in the ﬁrst model and 15.2 % in the second model on
the sixth domain ‘Participation in society’. Anxiety and depressive disorder were effect
modiﬁers of the relationship between somatization and mobility, self-care, interpersonal
interactions, household activities and work activities. Because the effect of somatization
Table 2
Regression coefﬁcients of the cross-sectional linear regression analysis modeling the association between somatization and disability (weighted, N= 1545)
WHODAS domains (N) Model 1† Model 2‡
B (CI)⁎ (Δ) R2 # B (CI) ⁎ Δ R2 #
Total score
(N= 1545)
1.47 (1.38; 1.55)⁎⁎ .418 1.08 (0.98; 1.17)⁎⁎ .167
1. Cognition 1.48 (1.37; 1.59)⁎⁎ .312 1.06 (0.94; 1.18)⁎⁎ .118
2. Mobility⁎⁎⁎ 1.15 (1.03; 1.27)⁎⁎ .170 No anx/dep: 0.83 (0.67; 0.99)⁎⁎
Anxiety: 0.73 (0.36; 1.09)⁎⁎
Depression: 1.09 (0.59; 1.58)⁎⁎
Comorbid: 1.66 (1.25; 2.06)⁎⁎
.088
3. Self-care 0.84 (0.75; 0.92)⁎⁎ .201 No anx/dep: 0.57 (0.45; 0.68)⁎⁎
Anxiety: 0.73 (0.46; 1.00)⁎⁎
Depression: 0.73 (0.37; 1.09)⁎⁎
Comorbid: 1.08 (0.78; 1.37)⁎⁎
.096
4. Interpersonal interactions 1.45 (1.31; 1.58)⁎⁎ .225 No anx/dep: 1.02 (0.84; 1.19)⁎⁎
Anxiety: 1.30 (0.89; 1.71)⁎⁎
Depression: 0.16 (−0.40; 0.71)
Comorbid: 0.29 (−0.17; 0.74)
.076
5h. House-hold activities 2.05 (1.89; 2.21)⁎⁎ .288 No anx/dep: 1.64 (1.42; 1.85)⁎⁎
Anxiety: 1.44 (0.94; 1.94)⁎⁎
Depression: 1.35 (0.67; 2.03)⁎⁎
Comorbid: 0.78 (0.22; 1.33) ⁎⁎
.117
5w. Work activities§
(N= 1116)
1.91 (1.71; 2.12)⁎⁎ .237 No anx/dep: 1.61 (1.35; 1.88)⁎⁎
Anxiety: 1.57 (0.95; 2.20)⁎⁎
Depression: 0.33 (−0.47; 1.13)
Comorbid: 0.73 (−0.05; 1.51)
.108
6.Participation in society 1.69 (1.58; 1.80)⁎⁎ .375 1.25 (1.13; 1.37)⁎⁎ .152
No anx/dep = no anxiety and/or depressive disorder; comorbid = comorbid anxiety and depressive disorder.
⁎ Unstandardized regression coefﬁcients of somatization (with 95% conﬁdence intervals).
⁎⁎ P-value ≤ .001.
⁎⁎⁎ Model adjusted for chronic diseases.
† Model adjusted for confounding background variables (if any).
‡ Model adjusted for background variables and anxiety and depressive disorder.
# Delta R square, indicating the contribution of somatization to disability.
§ This domain was only applicable if participant was employed or attended school.
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sence of effect modiﬁcation), we report separate regression coefﬁcients for the subgroups
depression only, anxiety only, comorbid depression and anxiety, and no anxiety or depres-
sion. The relationship between somatization and the subdomains of disability was stron-
gest for people with comorbid disorder on domain 2 and 3. The effect of somatization
on interpersonal interactions was greatest for people with anxiety disorders. Lastly, the
correlation between somatization and household and work activities was strongest for
people without anxiety or depressive disorder.Table 3
Regression coefﬁcients of the longitudinal linear regression analysis modeling the association b
WHODAS domains (N) Model 1†
B (CI)⁎ (Δ)
Total score
(N= 1361)
1.35 (1.24; 1.45)⁎⁎ .31
1.Cognition 1.11 (1.00; 1.21)⁎⁎ .22
2. Mobility⁎⁎⁎ 0.84 (0.73; 0.95)⁎⁎ .12
3. Self-care 0.44 (0.37; 0.50)⁎⁎ .12
4.Interpersonal interactions 0.85 (0.74; 0.96)⁎⁎ .14
5h. House-hold activities 1.14 (1.01; 1.27)⁎⁎ .18
5w. Work activities§
(N= 1016)
0.92 (0.76; 1.08)⁎⁎ .12
6.Participation in society 1.10 (1.00; 1.20)⁎⁎ .31
No anx/dep = no anxiety and/or depressive disorder; comorbid = comorbid anxiety and depr
⁎ Unstandardized regression coefﬁcients of somatization (with 95% conﬁdence intervals).
⁎⁎ P-value ≤ .001.
⁎⁎⁎ Model adjusted for chronic diseases.
† Model adjusted for background variables (if any).
‡ Model adjusted for background variables and anxiety and depressive disorder.
# Delta R square, indicating the contribution of somatization to disability.
§ This domain was only applicable if participant was employed or attended school.Longitudinal association between somatization and disability
For the longitudinal analyses, the sample was reduced to 1361 participants (88.1%)
due to non-response at one year follow-up. The non-responderswere not signiﬁcantly dif-
ferent from the study population regarding gender and age.
Table 3 presents the regression coefﬁcients (B) expressing the association between
somatization at baseline and disability after one year. Somatizationwas found to be signif-
icantly associated with disability after one year of follow-up (B: 1.35, CI: 1.24–1.45).etween somatization and disability (weighted, N= 1361)
Model 2‡
R2 # B (CI) ⁎ Δ R2 #
7 1.09 (0.97; 1.20)⁎⁎ .157
8 0.87 (0.75; 1.00)⁎⁎ .107
1 0.75 (0.62; 0.87)⁎⁎ .073
2 0.35 (0.28; 0.42)⁎⁎ .061
6 No anx/dep: 0.67 (0.53; 0.81)⁎⁎
Anxiety: 0.60 (0.26; 0.94)⁎⁎
Depression: 0.13 (−0.44; 0.70)
Comorbid: 0.08 (−0.31; 0.47)
.057
3 0.90 (0.76; 1.05)⁎⁎ .086
0 No anx/dep: 0.96 (0.75; 1.16)⁎⁎
Anxiety: 0.84 (0.33; 1.35)⁎⁎
Depression:−0.25 (−1.04; 0.55)
Comorbid:−0.02 (−0.59; 0.55)
.082
7 0.91 (0.80; 1.03)⁎⁎ .136
essive disorder.
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of thevariance indisability after one year. Therewereno confounders identiﬁed in theﬁrst
model and depression–anxiety status was no effect modiﬁer in the second model. When
depression–anxiety status was added to the model, the unique contribution of somatiza-
tion to disability after one year was reduced to 15.7%.
The explained variance for the domains ranged from 12.0% in the domain ofWork ac-
tivities to 31.8% in the domain 'Participation in Society'. The number of chronic diseases
was again the only confounder and was identiﬁed in the relationship between somatiza-
tion and mobility. The unique contribution of somatization to disability ranged from
5.7% in domain 4 (Interpersonal interactions) to 13.6% in domain 6 (Participating in soci-
ety). Depression–anxiety statuswas identiﬁedas an effectmodiﬁer for the relationship be-
tween somatization anddisability ondomain4 and5 (interpersonal interactions andwork
activities), where the effect was largest for people without anxiety or depressive disorder.
Tables 2 and 3 suggest that the power of the studywas sufﬁcient to detect a signiﬁcant
contribution of somatization of 6–10% to the variance of disability.Discussion
The present study shows that somatization is associated with dis-
ability in primary care patients. Cross-sectionally, the contribution of so-
matization is substantial, explaining 41.8% of its variance. However, this
relationship between somatization and disability was partly accounted
for by anxiety and depressive disorders. Interestingly, after adjustment
for the effect of anxiety and depressive disorder, somatization was still
associated with disability. In addition, somatization was also associated
with disability after one year.
Consistent with previous ﬁndings, the association between somati-
zation and disability was substantial, also when the effect of depressive
and anxiety disorder was taken into account. Our results are in linewith
the previous study of Hoedeman and colleagues, who found a strong
relationship between high levels of somatic symptom severity and func-
tional limitations, sickness absence duration and discharge in sick-listed
employees [33]. However, they found that psychiatric comorbidity
(depressive, anxiety and panic disorder) did not contribute to a longer
duration of sickness absence. Barsky and colleagues have seen a correla-
tion between somatization and highermedical utilization and costs, but
independent of anxiety and depression and medical comorbidity [1].
However, Barsky et al. used a cross-sectional design allowing no conclu-
sions about cause-and-effect relationships.
In contrast tomost of the other studies, we used a longitudinal design.
In this primary care population, we found in the adjusted models a mod-
erate association between somatization and (long-term) disability. Ad-
justment for anxiety and depressive disorder took away part of the
effect of somatization on disability, possibly because of the association be-
tween somatization and anxiety anddepressive disorder on theonehand,
and the effect of anxiety anddepressive disorder ondisability on the other
hand. Those results are in line with previous studies that found a higher
impairment of every day functioning when patients have depression
and/or anxiety in addition to physical symptoms [7,34,35].
This study has several strengths, including the large sample size and
the longitudinal design. While the decreased functioning was noted in
prior cross-sectional studies, to our knowledge this is the ﬁrst study to
assess disability associatedwith somatization longitudinally among pri-
mary care patients.
Besides strengths, the study also has some potential limitations. First-
ly, the disability measures were based on self-report questionnaires. This
may result in more missing data than interview-administered versions.
However, byusingmissing value analysis,we tried tominimize the effects
of missing values. Another potential limitation is that we used the 4DSQ
somatization scale to measure somatization, which is measured as the
presence ofmultiple physical symptoms. Somatization is often operation-
alized by a lack of organic causality, deﬁned as ‘the expression of psycho-
logical illness through physical symptoms’ [2] or ‘repeated medical help-
seeking formultiplemedical symptomswithout organic disease’ [3]. Such
operationalizations are difﬁcult to assess in large-scale studies, as a panel
of experts is needed, or the patient's treating physician. Some somatic
symptoms may have had a medical basis, since we could not distinguish
with certainty between explained and unexplained symptoms becauseno medical evaluation was performed. The somatization scale measures
the presence of physical symptoms which remain often unexplained, for
example dizziness, painful muscles, back pain or palpitations. It is com-
mon to experience one or a few unexplained symptoms under stressful
circumstances [36,37]. However, if someone is experiencing many of
these symptoms, it implies somatization. In addition, it should be noticed
that we used continuous scores for somatization and disability, but cate-
gorical measures for anxiety and depressive disorders. Therefore, the ad-
justed association between somatization and disability could have been
overestimated.
Since somatization is a common problem in primary care patients, it
may be important to improve identiﬁcation of these patients.Wewould
advice GPs to pay more attention to medical unexplained physical
symptoms. The 4DSQ can be a helpful tool to detect patients who are
somatizing.
It may also be important to estimate the distinct roles of somatiza-
tion and anxiety or depressive disorder on disability, because the treat-
ment of somatization often differs to some extent from the treatment of
anxiety and depressive disorder. A greater emphasis on explanation, re-
laxation,motivation, activation and countering avoidance behaviormay
be needed. Perhaps an implementation of better communication strate-
gies might be helpful to improve health care. A multidisciplinary guide-
line and a GP guideline are available in the Netherlands for ‘somatically
insufﬁciently explained physical symptoms’ [38,39].
As the unique contribution of somatization to disability is substantial,
treatment of somatization might be useful to decrease disability in this
population. In patients with co-morbid anxiety and depressive disorder
who show signs of somatization, additional treatment focussing on anxi-
ety and depressive disorder may also be effective in reducing disability.
In conclusion, somatization contributed to disability in primary care
patients over and above anxiety and depressive disorder.
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